Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ORKA Oruka Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: ORKA
Price (delayed)
$11.19
Market cap
$418.96M
P/E Ratio
N/A
Dividend/share
$19.36
EPS
-$1.81
Enterprise value
$336.33M
Highlights
Oruka Therapeutics's EPS has soared by 53% from the previous quarter
Oruka Therapeutics's net income has increased by 7% QoQ
The company's equity fell by 4.6% QoQ
Key stats
What are the main financial stats of ORKA
Market
Valuations
Earnings
Shares outstanding
37.44M
Market cap
$418.96M
Enterprise value
$336.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$87.98M
Net income
-$78.08M
EBIT
-$77.58M
EBITDA
-$77.36M
Free cash flow
-$77.38M
Per share
Balance sheet
Liquidity
EPS
-$1.81
EPS diluted
-$1.81
Free cash flow per share
-$1.86
Book value per share
$9.74
Revenue per share
$0
TBVPS
$9.05
Total assets
$377.11M
Total liabilities
$12.39M
Debt
$947,000
Equity
$364.73M
Working capital
$340.36M
Debt to equity
0
Current ratio
30.03
Quick ratio
29.78
Net debt/EBITDA
1.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-25.6%
Return on equity
-27.8%
Return on invested capital
-52.5%
Return on capital employed
-21.2%
Return on sales
N/A
Dividend yield
172.98%
DPS
$19.36
Payout ratio
N/A
ORKA stock price
How has the Oruka Therapeutics stock price performed over time
Intraday
0.99%
1 week
2.66%
1 month
2.1%
1 year
-75.65%
YTD
-42.29%
QTD
9.06%
Financial performance
How have Oruka Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.98M
Net income
-$78.08M
Gross margin
N/A
Net margin
N/A
Oruka Therapeutics's net income has increased by 7% QoQ
Price vs fundamentals
How does ORKA's price correlate with its fundamentals
Growth
What is Oruka Therapeutics's growth rate over time
Valuation
What is Oruka Therapeutics stock price valuation
P/E
N/A
P/B
1.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Oruka Therapeutics's EPS has soared by 53% from the previous quarter
ORKA's price to book (P/B) is 100% lower than its 5-year quarterly average of 1153.6 and 5% lower than its last 4 quarters average of 1.2
The company's equity fell by 4.6% QoQ
Efficiency
How efficient is Oruka Therapeutics business performance
Oruka Therapeutics's return on assets has increased by 34% QoQ
The return on equity has grown by 30% since the previous quarter
Oruka Therapeutics's return on invested capital has decreased by 2.9% QoQ
Dividends
What is ORKA's dividend history
DPS
$19.36
Dividend yield
172.98%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Oruka Therapeutics financials performed over time
Oruka Therapeutics's total liabilities has decreased by 10% QoQ
The company's total assets fell by 4.8% QoQ
The company's debt is 100% lower than its equity
The company's equity fell by 4.6% QoQ
The company's debt fell by 2.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.